Price Alert

Rapport Therapeutics Inc.... (RAPP)

NASDAQ: RAPP · Real-Time Price · USD

26.63

0.19 (0.72%)

At close: Oct 08, 2025, 10:10 AM

0.72% (1D)

Bid	19.24
Market Cap	971.93M
Revenue (ttm)	720K
Net Income (ttm)	-88.31M
EPS (ttm)	1.2
PE Ratio (ttm)	22.19
Forward PE	-7.08
Analyst	Buy
Dividends	n/a

Ask	34.3
Volume	28,927
Avg. Volume (20D)	710,929
Open	27.00
Previous Close	26.44
Day's Range	26.03 - 27.07
52-Week Range	6.43 - 42.27
Beta	1.71
Ex-Dividend Date	n/a

About RAPP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RAPP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RAPP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

4 weeks ago

-20.09%

Rapport Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

4 weeks ago

-10.93%

Rapport Therapeutics shares are trading lower after the company announced a $250 million public offering.

News

19 hours ago · businesswire.com

Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation

SAN FRANCISCO & AUSTIN, Texas & EDINBURGH, Scotland--(BUSINESS WIRE)-- #AI--Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation.

3 weeks ago · seekingalpha.com

Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Rapport Therapeutics, Inc. (NASDAQ:RAPP ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT Company Participants Abraham Ceesay - CEO, Preside...

3 weeks ago · zacks.com

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

4 weeks ago · invezz.com

Rapport stock plunges 18% on Wednesday: what went wrong after 200% rally

Rapport stock (NASDAQ: RAPP) cratered 18% on Wednesday as the market delivered a harsh verdict on its latest funding strategy. The catalyst was as predictable as it was painful.